Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection (PURPOSE 2)
Eine doppelblinde, multizentrische, randomisierte Phase-3-Studie zur Bewertung der Wirksamkeit und Sicherheit von zweimal jährlich subkutan verabreichtem langwirksamem Lenacapavir zur HIV-Präexpositionsprophylaxe bei Cis-Männern, Transgender-Frauen, Transgender-Männern und geschlechtsneutralen Personen ≥ 16 Jahren Alter, die Sex mit männlichen Partnern haben und ein Risiko für eine HIV-Infektion haben
The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV-1 infection.
The primary objective of this study is to evaluate the efficacy of LEN for HIV-1 pre-exposure prophylaxis (PrEP) in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth at risk of HIV-1 infection.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Buenos Aires, Argentinien, 1072
- Hospital General de Agudos JM Ramos Mejia
-
Buenos Aires, Argentinien, B7600
- Instituto de Investigaciones Clinicas Mar del Plata
-
Buenos Aires, Argentinien, 1202
- Fundacion Huesped
-
-
-
-
-
Belo Horizonte - MG, Brasilien, 30130-100
- Unidade de Pesquisa Clinica em Vacinas (UPqVac) da Faculdade de Medicina da Universidade
-
Canela-Salvador, Brasilien, 40110-060
- Fundação Bahiana de Infectologia
-
Manauas, Brasilien, 69040-000
- Fundação de Medicina Tropical Doutor Heitor Vieira Dourado / Fundação Medicina Tropical do Amazonas - FMT/IMT/AM
-
Nova Iguaçu, Brasilien, 26030-380
- Hospital General de Nova Iguaçu - HGNI
-
Porto Alegre, Brasilien, RS 91350 200
- Grupo Hospitalar Conceição/ Hospital Nossa Senhora da Conceição S.A.
-
Rio de Janeiro, Brasilien, 21040-360
- Instituto Nacional de Infectologia Evandro Chagas / Fundação Oswaldo Cruz - INI FIOCRUZ
-
São Paulo, Brasilien, 01246-903
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
-
São Paulo, Brasilien, 04121-000
- Centro de Referência e Treinamento DST/AIDS
-
São Paulo, Brasilien, 06519-332
- Center for Management and Research. SPDM-Paulista Association for the Development of Medicine-Hospital São Paulo/Federal
-
-
-
-
-
Guadalajara C.P., Mexiko, 44160
- Centro de Investigacion Farmaceutica Especializada de Occidente S.C.
-
-
-
-
-
Barranco, Peru, 15063
- Asociacion Civil Impacta Salud y Educacion - Sede Barranco
-
Callao, Peru, 7006
- Instituto de Medicina Tropical "Daniel Alcides Carrion", Facultad de Medicina Humana, UNMSM
-
Iquitos, Peru
- Asociacion Civil Selva Amazonica
-
Lima, Peru, 15001
- Via Libre
-
Lima, Peru, 15088
- Asociacion Civil Impacta Salud y Educacion - Sede San Miguel
-
-
-
-
PR
-
San Juan, PR, Puerto Rico, 00717
- Ararat Research Center
-
San Juan, PR, Puerto Rico, 00909
- Centro Ararat- San Juan
-
-
-
-
-
Cape Town, Südafrika, 7925
- Desmond Tutu Health Foundation
-
Johannesburg, Südafrika, 2038
- Wits Reproductive Health and HIV Institute (Wits RHI)
-
Pretoria, Südafrika, 87
- The Aurum Institute: Pretoria Clinical Research Centre
-
Soshanguvhe, Südafrika, 0152
- Setshaba Research Centre
-
Tembisa, Südafrika, 1632
- The Aurum Institute Tembisa CRC, Clinic 4
-
Vincent, Südafrika, 5217
- FPD-DTHF Ndevana Commuity Research Site
-
-
-
-
-
Bangkok, Thailand, 10330
- King Chulalongkorn Memorial Hospital
-
Bangkok, Thailand, 10400
- Ramathibodi Hospital, Mahidol University
-
Bangkok, Thailand, 10330
- Institute of HIV Research and Innovation
-
Bangkok, Thailand, 10330
- The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS research Centre
-
Chiang Mai, Thailand, 50200
- Research Institute for Health Sciences, Chiang Mai University
-
Khon Kaen, Thailand, 40002
- Srinagarind Hospital, Khon Kaen University
-
Nonthaburi, Thailand, 11000
- Bamrasnaradura Infectious Disease Institute
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- UAB Sexual Health Research Clinic
-
-
California
-
Loma Linda, California, Vereinigte Staaten, 92354
- Loma Linda University Clinical Trial Center Clinic
-
Los Angeles, California, Vereinigte Staaten, 90069
- Mills Clinical Research
-
Los Angeles, California, Vereinigte Staaten, 90036
- Ruane Clinical Research Group Inc.
-
Los Angeles, California, Vereinigte Staaten, 90038
- UCLA CBAM Vine Street Clinic
-
Los Angeles, California, Vereinigte Staaten, 90059
- Charles R. Drew University of Medicine and Science (CDU) - Clinical Translational Research Center (CTRC)
-
Los Angeles, California, Vereinigte Staaten, 90502
- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
Palm Springs, California, Vereinigte Staaten, 92262
- BIOS Clinical Research
-
San Diego, California, Vereinigte Staaten, 92103
- UCSD Anti Viral Research Center
-
San Francisco, California, Vereinigte Staaten, 94102
- Optimus Medical Group
-
San Francisco, California, Vereinigte Staaten, 94102
- Bridge HIV at the San Francisco Department of Public Health
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- University of Colorado Clinical and Translational Research Centers (CTRC)
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06510
- Yale University, School of Medicine
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20009
- Whitman-Walker Institute Inc.
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20017
- Washington Health Institute
-
-
Florida
-
Fort Lauderdale, Florida, Vereinigte Staaten, 33308
- Therafirst Medical Center
-
Fort Lauderdale, Florida, Vereinigte Staaten, 33316
- Gary Richmond, MD, PA
-
Ft. Pierce, Florida, Vereinigte Staaten, 34982
- Midway Immunology & Research Center, LLC
-
Jacksonville, Florida, Vereinigte Staaten, 32207
- CAN Community Health Clinic
-
Miami, Florida, Vereinigte Staaten, 33136
- University of Miami Miller School of Medicine Division of Infectious Disease Research - Converge Miami
-
Miami Gardens, Florida, Vereinigte Staaten, 33055
- CAN Community Health
-
Orlando, Florida, Vereinigte Staaten, 32803
- Orlando Immunology Center
-
Sarasota, Florida, Vereinigte Staaten, 34237
- CAN Community Health
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30303
- Emory University
-
Atlanta, Georgia, Vereinigte Staaten, 30308
- Emory University Hospital Midtown Infectious Disease Clinic
-
Atlanta, Georgia, Vereinigte Staaten, 30030
- The Hope Clinic at Emory University
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60613
- Howard Brown Health Center
-
Chicago, Illinois, Vereinigte Staaten, 60612
- RMR Core Center
-
Chicago, Illinois, Vereinigte Staaten, 60612
- University of Illinois at Chicago, Department of Medicine, Division of Infectious Diseases, Project WISH
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Indiana University Infectious Diseases Research
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40503
- Baptist Health Lexington
-
Louisville, Kentucky, Vereinigte Staaten, 40241
- Norton Infectious Disease Specialists
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70119
- LSU-CrescentCare Sexual Health Center- New Orleans Community Health Center
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Johns Hopkins University School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- The Fenway Institute
-
-
Michigan
-
Berkley, Michigan, Vereinigte Staaten, 48072
- Be Well Medical Center
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Henry Ford Hospital
-
-
Mississippi
-
Jackson, Mississippi, Vereinigte Staaten, 39202
- Open Arms Healthcare Center
-
-
Missouri
-
Kansas City, Missouri, Vereinigte Staaten, 64111
- KC CARE Health Center
-
-
New Jersey
-
Newark, New Jersey, Vereinigte Staaten, 07102
- St. Michael's Medical Center
-
Somers Point, New Jersey, Vereinigte Staaten, 08244
- South Jersey Infectious Disease
-
-
New York
-
New York, New York, Vereinigte Staaten, 10029
- Icahn School of Medicine at Mount Sinai- Mount Sinai Downtown
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27514
- NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill
-
Greensboro, North Carolina, Vereinigte Staaten, 27401
- Cone Health/Regional Center for Infectious Disease Research Center
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27103
- Wake Forest University Health Sciences
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45267
- University of Cincinnati
-
Columbus, Ohio, Vereinigte Staaten, 43210
- The Ohio State University Wexner Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Penn Prevention Unit
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Philadelphia FIGHT Community Health Centers, Jonathan Lax Treatment Center
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Medical University of South Carolina, Infectious Disease Clinic
-
Columbia, South Carolina, Vereinigte Staaten, 29203
- Prisma Health-Midlands Clinical Research Unit
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Prisma Health Internal Medicine Clinic
-
-
Tennessee
-
Memphis, Tennessee, Vereinigte Staaten, 38105
- St Jude Children's Research Hospital
-
Memphis, Tennessee, Vereinigte Staaten, 38103
- Methodist University Hospital/University of Tennessee Health Science Center, Clinical Research Center
-
Nashville, Tennessee, Vereinigte Staaten, 37208
- Meharry Medical College Clinical and Transitional Research Center
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78705
- Central Texas Clinical Research
-
El Paso, Texas, Vereinigte Staaten, 79915
- Centro San Vincente
-
Houston, Texas, Vereinigte Staaten, 77098
- The Crofoot Research Center, INC
-
Houston, Texas, Vereinigte Staaten, 77009
- UT Health Science Center at Houston
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98104
- Ofiice of Dr. Peter Shalit, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
Incidence Phase
-
CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.
-
HIV-1 status unknown at screening and no prior HIV-1 testing within the last 3 months.
-
Sexually active with ≥ 1 partner assigned male at birth (condomless receptive anal sex) in the last 12 months and 1 of the following:
- Condomless receptive anal sex with ≥ 2 partners in the last 12 weeks.
- History of syphilis, rectal gonorrhea, or rectal chlamydia in the last 24 weeks.
- Self-reported use of stimulants with sex in the last 12 weeks.
Randomized Phase
- Negative local rapid fourth generation HIV-1/2 Ab/Ag, central fourth generation HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT).
- Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min at screening according to the Cockcroft-Gault formula for creatinine clearance (CLcr).
Key Exclusion Criteria:
Incidence Phase
- Prior use of HIV PrEP (including F/TDF or F/TAF) or HIV postexposure prophylaxis (PEP) in the past 12 weeks or any prior use of long-acting systemic PrEP (including cabotegravir or islatravir).
- Prior recipient of an HIV vaccine or HIV broadly neutralizing antibody formulation.
Randomized Phase
- Acute viral hepatitis A, B or C or evidence of chronic hepatitis B or C infection.
- Severe hepatic impairment or a history of or current clinical decompensated liver cirrhosis.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF
Participants will receive the following for up to approximately 52 weeks:
Participants will receive oral LEN if SC injections are not available. |
Tablets administered orally without regard to food
Andere Namen:
Administered via SC injections
Andere Namen:
Tablets administered orally |
|
Experimental: Randomized Blinded Phase: Placebo LEN + F/TDF
Participants will receive the following for up to approximately 52 weeks:
Participants will receive oral LEN placebo if SC injections are not available. |
Tablets administered orally
Andere Namen:
Administered via SC injections Tablets administered orally |
|
Experimental: LEN Open-Label Extension (OLE) Phase
Participants will be offered entry into LEN OLE Phase, following completion of primary analysis, if LEN demonstrates acceptable safety and efficacy in the Randomized Blinded Phase. Participants randomized to LEN will continue to receive SC LEN 927 mg, every 26 weeks (± 7 days), and have study visits every 13 weeks (± 7 days). Participants randomized to F/TDF will switch to SC LEN 927 mg on OLE Day 1, Week 26 and every 26 weeks thereafter. Participants will also receive oral LEN 600 mg on OLE Days 1 and 2. All participants in LEN OLE Phase will complete the phase, once LEN becomes available or the sponsor decides to discontinue the study, whichever happens first. After completing LEN OLE Phase or study discontinuation, participants will transition to local PrEP, including LEN or other options. If a participant exits early, they will complete an early study drug discontinuation (ESDD), be referred to local PrEP services if needed, and have a 30-day follow-up visit. |
Tablets administered orally without regard to food
Andere Namen:
Administered via SC injections
Andere Namen:
|
|
Experimental: Pharmacokinetic (PK) Tail Phase
Participants who prematurely discontinue study drug during the Randomized Blinded Phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase will transition to the PK Tail Phase. Participants will receive oral F/TDF (or Emtricitabine/Tenofovir Alafenamide (F/TAF) for US participants only) once daily for 78 weeks to cover the PK tail and complete visits every 13 weeks (+/- 7 days). Upon unblinding, participants who were randomized to F/TDF in the Randomized Blinded Phase who decline to participate in the LEN OLE Phase will complete the ESDD visit, transition to local HIV prevention services, and return for a 30-day follow-up visit. |
Tablets administered orally
Andere Namen:
F/TAF tablets administered orally once daily
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)
Zeitfenster: Incidence Phase Screening Visit (Day 1)
|
bHIV per 100 PY in the Incidence Phase was calculated using RITA. The RITA incorporated HIV-1 testing results and recency assay testing results to estimate the bHIV. Recency assay testing was performed for participants in the All Screened Set found to have HIV-1 infection at the Incidence Phase Screening Visit as defined below. Participants were considered to have recent HIV-1 infection if the normalized optical density (ODn) was below 1.5 threshold using the Sedia limiting antigen avidity enzyme immunoassay (LAg-EIA) and the HIV-1 RNA (viral load) was > 75 copies/mL of blood. HIV-1 infection was defined as participants having at least one of the following central lab results at the Incidence Phase screening visit:
|
Incidence Phase Screening Visit (Day 1)
|
|
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set)
Zeitfenster: Up to 149 weeks
|
HIV-1 incidence per 100 PY for LEN was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. bHIV incidence per 100 PY in All Screened Set was estimated as described in outcome measure#1. |
Up to 149 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to F/TDF
Zeitfenster: Up to 149 weeks
|
HIV-1 incidence per 100 PY was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. |
Up to 149 weeks
|
|
Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN
Zeitfenster: Up to 149 weeks
|
A participant was defined as adherent to LEN if they have received all per-protocol administrations of LEN within 28 weeks since the previous administration. The incidence of HIV-1 infection per 100 PY calculation is defined in outcome measure #2. |
Up to 149 weeks
|
|
Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
Zeitfenster: First dose date up to 184 weeks
|
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily have a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. |
First dose date up to 184 weeks
|
|
Randomized Blinded Phase: Percentage of Participants Experiencing Grade 3 or Higher Laboratory Abnormalities
Zeitfenster: First dose date up to 184 weeks
|
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the last exposure date for participants who permanently discontinued study drug, or the last available date in the database snapshot for participants who were still on treatment at the time of an analysis. The division of acquired immunodeficiency syndrome toxicity grading scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that do not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening. Percentages were rounded off. |
First dose date up to 184 weeks
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Gilead Study Director, Gilead Sciences
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-yearly lenacapavir PrEP in cisgender gay men, transgender women and men, and gender-diverse people (PURPOSE 2). Presented at: HIV Drug Therapy Glasgow; November 10-13, 2024; Glasgow, United Kingdom.
- Kelley CF, Acevedo-Quinones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sanchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O; PURPOSE 2 Study Team. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med. 2025 Apr 3;392(13):1261-1276. doi: 10.1056/NEJMoa2411858. Epub 2024 Nov 27.
- Cespedes M, Das M, Hojilla JC, Blumenthal J, Mounzer K, Ramgopal M, Hodge T, Torres TS, Peterson C, Shibase S, Elliott A, Demidont AC, Callaghan L, Watson CC, Carter C, Kintu A, Baeten JM, Ogbuagu O. Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP). PLoS One. 2022 Jun 3;17(6):e0267780. doi: 10.1371/journal.pone.0267780. eCollection 2022.
- Cantos Lucio VD, Mngadi K, Supparatpinyo K, et al. From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI 2026); February 22-25, 2026; Denver, CO. Abstract 129.
- Kwan TH, Chan DPC, Lee SS. Utilisation of HIV pre-exposure prophylaxis and preferences of alternative long-acting modalities among men who have sex with men in Hong kong: a cross-sectional study. BMC Public Health. 2025 Dec 26;26(1):361. doi: 10.1186/s12889-025-26025-5.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Pharmazeutische Präparate
- Nukleinsäuren, Nukleotide und Nukleoside
- Purines
- Desoxycytidin
- Cytidin
- Pyrimidin -Nucleoside
- Pyrimidine
- Organophosphorverbindungen
- Nukleoside
- Desoxyribonukleoside
- Organophosphonate
- Adenin
- Drogenkombinationen
- Tenofovir
- Emtricitabine
- Wirkstoffkombination Emtricitabin, Tenofovir Disoproxil Fumarat
- Lenacapavir
- Emtricitabine Tenofovir Alafenamid
Andere Studien-ID-Nummern
- GS-US-528-9023
- DOH-27-102021-6681 (Andere Kennung: South African National Clinical Trial Registry)
- 2023 (US NIH Stipendium/Vertrag)
- 2023-001025-23 (EudraCT-Nummer)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .